Home >>
Article >>
Hereditary Tyrosinemia Type 1 (HT-1): Causes, Symptoms, Diagnosis, and Treatment
Hereditary Tyrosinemia Type 1 (HT-1): Causes, Symptoms, Diagnosis, and Treatment
A Complete Guide to Hereditary Tyrosinemia Type 1 (HT-1)
Hereditary tyrosinemia type 1 (HT-1) is one of the most serious inherited metabolic disorders of childhood. Left untreated, it can lead to liver failure, kidney damage, and liver cancer at a very young age. Yet with early diagnosis and the right treatment — chiefly the medicine nitisinone combined with a special diet — most children today can live far healthier lives than was ever possible a few decades ago.
This guide from Ikris Pharma Network explains what HT-1 is, why it happens, how it is recognized and diagnosed, and how nitisinone has transformed its treatment.
What is Hereditary Tyrosinemia Type 1?
Hereditary tyrosinemia type 1 is a rare, inherited disorder in which the body cannot fully break down the amino acid tyrosine. Tyrosine is normally processed in the liver through a five-step enzyme pathway. In HT-1, the final enzyme in that pathway — fumarylacetoacetate hydrolase (FAH) — is deficient.
When FAH is missing or not working, the breakdown process stalls and toxic intermediate compounds accumulate, including fumarylacetoacetate, maleylacetoacetate, and succinylacetone. These toxins are especially harmful to the liver and kidneys, and over time they raise the risk of hepatocellular carcinoma (liver cancer).
HT-1 is an autosomal recessive condition, meaning a child must inherit a faulty FAH gene from both parents to be affected. Its worldwide incidence is roughly 1 in 100,000 newborns, with higher rates in certain populations such as the Saguenay–Lac-Saint-Jean region of Quebec and parts of Scandinavia.
What Causes HT-1?
The root cause of HT-1 is a mutation in the FAH gene, which provides instructions for making the fumarylacetoacetate hydrolase enzyme. Because the disorder is recessive, carriers (parents with one faulty copy) usually have no symptoms.
In simple terms:
- The body takes in tyrosine from protein in food.
- Tyrosine is normally broken down step by step into harmless products.
- In HT-1, the last step fails because FAH is deficient.
- Toxic by-products build up and poison the liver and kidneys.
Symptoms of Hereditary Tyrosinemia Type 1:
Symptoms can vary depending on how early the disease appears. Doctors often describe acute (before 6 months), sub-acute (6–12 months), and chronic (after 1 year) forms. The earlier symptoms appear, the more severe the disease tends to be.
Common early signs in infants include:
- Failure to thrive (poor weight gain and growth)
- Vomiting and diarrhea
- Jaundice (yellowing of the skin and eyes)
- An unusual "cabbage-like" or boiled-cabbage body odor
- An increased tendency to bleed or bruise easily
- Enlarged liver and abdomen
Features of more advanced or untreated disease can include:
- Liver problems — ranging from an enlarged liver to cirrhosis and life-threatening liver failure
- Kidney (renal tubular) dysfunction, which can lead to softening of the bones (rickets)
- Neurological crises that resemble porphyria — including pain, weakness, and, in severe cases, breathing difficulty
- Long-term risk of hepatocellular carcinoma (liver cancer)
Because early symptoms can be vague or absent, many infants pass through a "silent" phase — which is exactly why screening at birth is so important.
How is HT-1 Diagnosed?
Early diagnosis is critical because treatment works best when started before symptoms cause permanent damage. Diagnosis typically involves:
- Newborn screening: Many regions screen newborns using a dried blood spot. The most reliable and specific marker is succinylacetone, which is elevated in HT-1. (Tyrosine levels alone are unreliable and can give false-negative results, so succinylacetone-based screening is preferred.)
- Biochemical testing: Detecting elevated succinylacetone in blood and/or urine strongly supports the diagnosis. Alpha-fetoprotein may also be raised.
- Genetic (molecular) testing: Identifying mutations in both copies of the FAH gene confirms the diagnosis.
A key practical point: because some screening programs still rely on tyrosine rather than succinylacetone, a normal newborn screen does not always rule out HT-1. Clinicians maintain suspicion if a child later develops unexplained liver or kidney problems.
Treatment of Hereditary Tyrosinemia Type 1
There are three pillars to managing HT-1: nitisinone, dietary therapy, and lifelong monitoring. Liver transplantation is reserved for specific situations.
Nitisinone (NTBC) — The Cornerstone Medicine
Nitisinone, also known by its chemical abbreviation NTBC, is the primary drug treatment for HT-1. It was first shown to help patients in 1992 and was approved by the US FDA in 2002. It is marketed under brand names such as Orfadin and Nityr, and is available as capsules, tablets, and an oral suspension.
How nitisinone works: Rather than fixing the missing FAH enzyme, nitisinone acts upstream. It blocks an earlier enzyme in the tyrosine pathway called 4-hydroxyphenylpyruvate dioxygenase (HPPD). By stopping the pathway earlier, nitisinone prevents the formation of the toxic metabolites (including succinylacetone) that damage the liver and kidneys.
Why it matters: When nitisinone is started early — ideally in the newborn period — it can prevent acute liver crises, reduce kidney and bone complications, lower the risk of liver cancer, and greatly reduce the need for liver transplantation. Treatment response is monitored by measuring succinylacetone levels.
Important considerations:
- Nitisinone does not cure HT-1 or repair the underlying enzyme defect; it must be taken lifelong.
- Because nitisinone blocks tyrosine breakdown higher up, blood tyrosine levels rise. This is why a controlled diet is essential.
- The most notable side effects relate to the eyes (such as reversible corneal deposits, eye irritation, or sensitivity to light), which are linked to high tyrosine levels. Effects on blood cells can also occur, so monitoring is part of routine care.
Dosing and monitoring must always be individualized by a metabolic specialist; this article does not provide dosing instructions.
Low-Tyrosine, Low-Phenylalanine Diet
Because nitisinone causes tyrosine to accumulate, patients must follow a strict low-tyrosine and low-phenylalanine diet for life, usually with the help of special medical formulas and a metabolic dietitian. Diet and medicine work together: the drug blocks the toxic pathway, and the diet keeps tyrosine from rising to harmful levels.
Liver Transplantation: Before nitisinone, liver transplantation was often the only option. Today it is reserved for patients who do not respond adequately to nitisinone or who develop liver cancer.
Emerging Therapies:
Researchers are actively exploring gene therapy as a potential one-time, curative approach that would correct the FAH defect directly. These approaches remain investigational and are not yet approved, but they represent a hopeful direction for the future.
Prognosis: A Transformed Outlook
The outlook for HT-1 has changed dramatically. Untreated, the disease was frequently fatal in early childhood due to liver failure, bleeding, or neurological crises. With early diagnosis through newborn screening, prompt nitisinone treatment, and dietary management, the majority of children now avoid acute crises and survive into adulthood with a much-reduced risk of complications. Lifelong follow-up — including liver imaging and regular biochemical monitoring — remains essential.
How Ikris Pharma Network Supports Access to Nitisinone
Access to rare-disease medicines like nitisinone can be challenging in regions where the product is not locally registered or readily available. Ikris Pharma Network specializes in facilitating compliant, legal access to such treatments for importers, wholesalers, hospitals, NGOs, patients, and physicians worldwide, through Named Patient supply and managed-access pathways — with authentic sourcing, proper documentation, and reliable global delivery.
If you are from Asia, Africa, LATAM, Caribbean/North America, or Central America, and looking to access nitisinone from India, Ikris Pharma Network can help guide you through a compliant process.
Frequently Asked Questions (FAQ):
What is hereditary tyrosinemia type 1?
HT-1 is a rare inherited metabolic disorder in which a deficiency of the FAH enzyme prevents the body from fully breaking down the amino acid tyrosine, leading to toxic build-up that damages the liver and kidneys.
What is the main treatment for HT-1?
The main treatment is the medicine nitisinone (NTBC), taken daily together with a strict low-tyrosine and low-phenylalanine diet. Lifelong monitoring is required.
How does nitisinone work in tyrosinemia type 1?
Nitisinone blocks the enzyme HPPD earlier in the tyrosine pathway, preventing the formation of toxic metabolites such as succinylacetone that would otherwise harm the liver and kidneys.
Does nitisinone cure hereditary tyrosinemia type 1?
No. Nitisinone controls the disease and prevents complications but does not repair the underlying enzyme defect, so it must be taken for life alongside dietary therapy.
How is HT-1 diagnosed?
Through newborn screening and biochemical testing — with succinylacetone being the most reliable marker — and confirmed by genetic testing of the FAH gene.
Why is a special diet needed with nitisinone?
Because nitisinone causes tyrosine to accumulate in the blood, a low-tyrosine, low-phenylalanine diet is needed to prevent tyrosine-related side effects, such as eye problems.
What happens if HT-1 is left untreated?
Untreated HT-1 can cause liver failure, kidney dysfunction, rickets, neurological crises, and a high risk of liver cancer, and is often fatal in early childhood.
Disclaimer: This article is for general educational and informational purposes only and does not constitute medical advice. Hereditary tyrosinemia type 1 and nitisinone therapy must be managed by qualified metabolic and hepatology specialists. Medicine availability and access pathways vary by country-specific regulations.